Two-Year Sapien Data Affirms Durability, And The Importance Of Avoiding Leaks
This article was originally published in The Gray Sheet
Executive Summary
Mortality rates remained statistically indistinguishable after two years among patients receiving either Edwards Lifesciences’ Sapien transcatheter aortic heart valve or open surgical valve replacement in the firm’s PARTNER trial. Transcatheter aortic valve leaks were highlighted as a primary target for improving survival.
You may also be interested in...
TAVR Competitors Put Pressure On Edwards To Deliver On New Growth Drivers
Edwards is betting on next-generation Sapien devices and efforts towards a transcatheter mitral valve, as Medtronic and other competitors move closer to threatening the firm’s TAVR leadership position.
Sapien Heart Valve Gets FDA Panel Nod For High-Risk Surgical Patients
Edwards Lifesciences’ first-to-market transcatheter valve is safe and effective, and its benefits outweigh its risks in an expanded patient population, an FDA advisory panel says.
Sapien Maintains Big Benefit In Inoperable Patients At Two Years
Recent launch of the transcatheter aortic heart valve for patients too sick for open heart surgery may get a lift from data presented at TCT.